Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697696 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 511
- Enrollment target
NCT01697696 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 511 participants.
The verdict
NCT01697696, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 511 participants
- Enrollment target
Study Summary
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
Interventions
- DRUG Placebo
- DRUG NVA237
- DRUG Long-acting beta 2-agonist (LABA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01697696
The ClinicalTrials.gov registry entry for NCT01697696 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01697696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01697696 about?
NCT01697696 is a clinical study titled "Long Term Safety Study of NVA237 vs QAB149 in COPD Patients". The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
What is the current status of trial NCT01697696?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 511 participants. The study started on 2012-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01697696?
The interventions under investigation include: Placebo (DRUG), NVA237 (DRUG), Long-acting beta 2-agonist (LABA) (DRUG).
Who is sponsoring clinical trial NCT01697696?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.